Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma...

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Anaplastic lymphoma kinase (ALK) is a cell surface receptor overexpressed on certain pediatric solid tumors.
• Chimeric antigen receptor (CAR)-based immunotherapy is a promising approach for cancer treatment.

Purpose of the Study:

• To explore the utility of targeting ALK with CAR T-cells for pediatric solid tumors.
• To investigate the factors influencing ALK CAR T-cell efficacy, including target antigen density and CAR expression levels.

Main Methods:

• Engineered T-cells expressing an ALK-specific CAR with a 4-1BB-CD3ζ signaling domain.
• Assessed CAR T-cell activity against ALK-expressing tumor lines and in neuroblastoma xenograft models.
• Investigated the impact of ALK target density, CAR expression, and receptor internalization on T-cell function.

Main Results:

• ALK CAR T-cells lysed ALK-expressing tumor lines and produced interferon-gamma.
• Limited anti-tumor efficacy was observed in neuroblastoma models, correlated with insufficient ALK target density.
• CAR T-cells showed rapid, antigen-induced receptor internalization.
• CAR functionality was found to be regulated by a stoichiometric relationship between CAR density and target antigen density.

Conclusions:

• The anti-tumor efficacy of ALK CAR T-cells is significantly influenced by the balance between CAR receptors and target antigens.
• Modulating these stoichiometric relationships may allow for precise tuning of CAR T-cell activity for improved therapeutic outcomes.